Question 1

Does Goldman Sachs Group own PTGX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Goldman Sachs Group holds 812,852 shares of PTGX (Protagonist Therapeutics), worth $99.6M.

Question 2

How many shares of PTGX does Goldman Sachs Group own?

Accepted Answer

As of its Q2 2026 13F, Goldman Sachs Group holds 812,852 shares of PTGX (Protagonist Therapeutics).

Question 3

What is Goldman Sachs Group's PTGX position worth?

Accepted Answer

As of its Q2 2026 13F, Goldman Sachs Group's PTGX position is worth $99.6M.

Question 4

Is Goldman Sachs Group buying or selling PTGX?

Accepted Answer

In Q2 2026, Goldman Sachs Group increased its PTGX position by 33,907 shares (+4.4%).

Question 5

When did Goldman Sachs Group first buy PTGX?

Accepted Answer

Goldman Sachs Group already held PTGX in its Q2 2022 13F, the earliest on record, and has listed it in 17 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	812,852	+4.3%	$99.6M	0.0%	$122.58	31
2026-Q1	Decreased	778,945	-19.0%	$82.1M	0.0%	$105.40	0
2025-Q4	Increased	961,149	+22.9%	$83.9M	0.0%	$87.34	36
2025-Q3	Increased	781,711	+0.6%	$51.9M	0.0%	$66.43	29
2025-Q2	Increased	777,307	+39.9%	$43M	0.0%	$55.27	39
2025-Q1	Decreased	555,551	-26.8%	$26.9M	0.0%	$48.36	0
2024-Q4	Decreased	758,690	-7.7%	$29.3M	0.0%	$38.60	0
2024-Q3	Increased	821,856	+39.1%	$37M	0.0%	$45.00	38